STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Liquidia Corporation SEC Filings

LQDA Nasdaq

Welcome to our dedicated page for Liquidia Corporation SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Tracking Liquidia’s clinical milestones can feel like navigating a labyrinth of FDA language, trial statistics, and licensing footnotes. Each new Liquidia 8-K material events explained notice might include pivotal updates on YUTREPIA’s path to approval, while a single Form 4 could show an insider buying shares ahead of a data read-out. Our AI-driven platform decodes those complexities so you can focus on what matters, delivering Liquidia SEC filings explained simply the moment they hit EDGAR.

Stop skimming hundred-page PDFs. Stock Titan’s engine extracts the cash-runway tables from every Liquidia quarterly earnings report 10-Q filing, highlights trial spend buried inside the Liquidia annual report 10-K simplified, and flags Liquidia proxy statement executive compensation details side by side with peer data. Need to watch executive moves? Receive Liquidia Form 4 insider transactions real-time alerts that list each Liquidia executive stock transactions Form 4 in context—share price, option type, and historical buying patterns.

Whether you’re comparing treprostinil royalty streams or assessing dilution risk from future capital raises, our coverage spans every filing type—from 10-K, 10-Q, and 8-K to Section 16 reports—updated in seconds. AI-powered summaries, keyword search across historical documents, and exportable tables let you perform rapid Liquidia earnings report filing analysis without specialized training. Use cases include:

  • Monitoring Liquidia insider trading Form 4 transactions before trial announcements
  • Understanding Liquidia SEC documents with AI for quicker valuation models
  • Tracking manufacturing scalability disclosures tied to PRINT® technology
Rhea-AI Summary

Liquidia Corp. (LQDA) insider activity: Chief Medical Officer Dr. Rajeev Saggar reported a PSU conversion and a tax-related sale. On 10/10/2025, 3,530 performance stock units converted into common stock on a one-for-one basis (code M). On 10/13/2025, 5,327 shares were sold at $23.41 (code S) pursuant to a Rule 10b5-1 plan adopted on December 15, 2023.

Following these transactions, the reporting person beneficially owns 247,930 shares, held directly. The sale was disclosed as covering taxes tied to the settlement of RSUs and PSUs initially granted on January 11, 2023 and January 11, 2024. The officer’s role is listed as Chief Medical Officer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Liquidia (LQDA)10/13/2025, she sold 1,691 shares of common stock at $23.41 per share under a Rule 10b5-1 plan adopted on December 15, 2023. The sale covered taxes tied to RSU settlements from awards granted on January 11, 2024 and July 1, 2024.

After the trade, she beneficially owned 141,439 shares. Her holdings include unvested RSUs from 2024 and 2025 grants and 5,312 shares acquired under the 2020 ESPP.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Filing
Rhea-AI Summary

Liquidia (LQDA) reported an insider transaction by its Chief Accounting Officer. On 10/13/2025, the officer sold 1,238 shares of common stock at $23.41 per share, coded “S,” pursuant to a Rule 10b5-1 plan adopted on December 15, 2023. The filing states the sale was to cover taxes tied to the settlement of restricted stock units granted on January 11, 2024.

After the transaction, the officer beneficially owned 185,411 shares, held directly. Holdings include unvested RSUs from prior grants and 11,869 shares acquired under the company’s 2020 Employee Stock Purchase Plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Liquidia Corp (LQDA) Chief Commercial Officer Scott Moomaw reported insider transactions. On 10/10/2025, 3,108 common shares were acquired upon settlement of performance stock units at $0 per unit. On 10/13/2025, 4,900 shares were sold at $23.41 pursuant to a Rule 10b5-1 plan; the filing notes the sale covered taxes related to prior RSU/PSU settlements.

Following these transactions, he beneficially owned 153,462 common shares directly and held 27,969 unvested RSUs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Liquidia (LQDA): Form 4 insider activity — The company’s General Counsel reported a conversion of performance stock units and a tax-related sale. On 10/10/2025, 3,758 PSUs converted into an equal number of common shares. On 10/13/2025, 7,839 common shares were sold at $23.41, effected under a Rule 10b5-1 plan adopted on 12/15/2023 and to cover taxes associated with prior RSU and PSU settlements.

Following these transactions, the reporting person directly held 576,017 common shares and had 33,826 derivative securities (PSUs) beneficially owned. An additional 14,500 shares are held indirectly by a spouse. PSU and RSU grants vest on stated schedules, with one-for-one PSU conversion into common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Liquidia (LQDA) officer Michael Kaseta (CFO and COO) reported a Form 4 showing equity settlement and a tax-related sale. On 10/10/2025, he acquired 5,828 shares of common stock upon the conversion of performance stock units, which convert one-for-one into common stock. On 10/13/2025, he sold 11,630 shares at $23.41 per share pursuant to a Rule 10b5-1 plan.

The filing states the sale was made to cover taxes from the settlement of previously granted RSUs and PSUs. Following the transactions, Kaseta beneficially owned 352,646 shares directly. The derivative table lists 52,453 derivative securities beneficially owned after the reported transactions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Amendment corrects previously omitted indirect holdings: Dr. Stephen M. Bloch, a director of Liquidia Corp (LQDA), amended a prior Form 4 to include 2,917,169 shares of common stock reported as indirectly held through Canaan VIII L.P. The filing states these shares are held by Canaan LP, whose sole general partner is Canaan Partners VIII LLC; investment and voting decisions are made by the managers of Canaan LLC. The Reporting Person disclaims beneficial ownership except for any pecuniary interest from his LLC interest. No derivative securities are reported in this amendment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Raman Singh, a director of Liquidia Corp (LQDA), exercised stock options and sold a portion of the resulting shares on 09/15/2025. He exercised a non-qualified option with a $2.51 strike to acquire 25,524 shares and a separate option with a $2.59 strike to acquire 20,000 shares. On the same date he sold 45,524 shares at a volume-weighted average price of $25.81, leaving him with beneficial ownership of 31,255 shares. The filing also discloses 18,396 restricted stock units granted on June 17, 2025 that had not vested as of the report date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Insider sale notice for LQDA: The filing reports a proposed sale of 45,524 common shares on 09/15/2025 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,175,042.73. The shares were acquired the same day via stock option exercise and paid for in cash. The filing shows 86,091,454 shares outstanding for the issuer. It also discloses a recent sale of 7,500 shares on 09/03/2025 generating $220,650.00 in gross proceeds. The signer certifies no undisclosed material adverse information.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

Raman Singh, a director of Liquidia Corporation (LQDA), reported a sale of common stock. The Form 4 shows a transaction dated 09/03/2025 where the reporting person sold 7,500 shares at a price of $29.42 each, leaving 31,255 shares beneficially owned after the sale. The filing notes the total includes 18,396 restricted stock units granted on June 17, 2025 that have not vested as of the Form 4 date. The Form 4 is signed by Raman Singh on 09/05/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

What is the current stock price of Liquidia Corporation (LQDA)?

The current stock price of Liquidia Corporation (LQDA) is $34.41 as of December 5, 2025.

What is the market cap of Liquidia Corporation (LQDA)?

The market cap of Liquidia Corporation (LQDA) is approximately 3.0B.
Liquidia Corporation

Nasdaq:LQDA

LQDA Rankings

LQDA Stock Data

2.95B
74.36M
13.61%
70.58%
19.88%
Biotechnology
Pharmaceutical Preparations
Link
United States
MORRISVILLE